Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740969 | 0.92 | CA1 (0.56) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL13128925 | 0.89 | HPGD (0.51) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL14161620 | 0.76 | POLB (0.60) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL15647634 | 0.76 | MAPT (0.60) | KMT2AMEN1MAPTL3MBTL1POLB | |
| SCHEMBL14160305 | 0.73 | PTK2B (0.52) | KMT2AMEN1MAPTL3MBTL1POLB | |
| SCHEMBL6546175 | 0.71 | PKM (0.55) | LMNAALDH1A1 | |
| SCHEMBL13128974 | 0.70 | ALDH1A1 (0.62) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL30343042 | 0.69 | L3MBTL1 (0.60) | CA1CA2CA5ACA7KMT2A | |
| SCHEMBL20981733 | 0.69 | L3MBTL1 (0.60) | CA1CA2CA5ACA7KMT2A | |
| SCHEMBL9311976 | 0.69 | RAB9A (0.64) | KMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | BCOR, CBR3, SULT1E1 | CA1 1487/4885CA2 304/4885CA5A 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.